Date | Price Target | Rating | Analyst |
---|---|---|---|
8/15/2024 | $76.00 → $90.00 | Sell → Neutral | UBS |
8/14/2024 | $100.00 → $85.00 | Buy → Hold | Stifel |
5/30/2024 | $83.00 | Sell | Goldman |
7/19/2023 | $90.00 | Neutral | Robert W. Baird |
6/30/2023 | $106.00 | Buy | CL King |
5/30/2023 | $104.00 | Equal-Weight → Overweight | Morgan Stanley |
4/24/2023 | $77.00 → $100.00 | Equal Weight → Overweight | Wells Fargo |
3/29/2023 | $127.00 → $79.00 | Buy → Sell | UBS |
UBS upgraded Medtronic from Sell to Neutral and set a new price target of $90.00 from $76.00 previously
Stifel downgraded Medtronic from Buy to Hold and set a new price target of $85.00 from $100.00 previously
Goldman initiated coverage of Medtronic with a rating of Sell and set a new price target of $83.00
4 - Medtronic plc (0001613103) (Issuer)
3 - Medtronic plc (0001613103) (Issuer)
4 - Medtronic plc (0001613103) (Issuer)
8-K - Medtronic plc (0001613103) (Filer)
8-K/A - Medtronic plc (0001613103) (Filer)
DEFA14A - Medtronic plc (0001613103) (Filer)
Product innovation driving growth across diversified health tech portfolio, including Automated Insulin Delivery, Transcatheter Aortic Valve Replacement, Pulsed Field Cardiac Ablation, Pain Stimulation, and Deep Brain Stimulation GALWAY, Ireland, Aug. 20, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its first quarter (Q1) of fiscal year 2025 (FY25), which ended July 26, 2024. Key Highlights Revenue of $7.9 billion, adjusted revenue of $8.0 billion, increased 2.8% as reported and 5.3% organicGAAP diluted earnings per share (EPS) of $0.80; non-GAAP diluted EPS of $1.23Company increases FY25 organic revenue growth and EPS guidanceMultiple franchises deliv
GALWAY, Ireland, Aug. 16, 2024 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 15, 2024, approved the company's cash dividend for the second quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on October 11, 2024, to shareholders of record at the close of business on September 27, 2024. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, h
NEW HOPE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its second quarter 2024 financial results and provided a business update. "Our work in hypertension and coronary artery disease aligns with a renaissance occurring in cardiac pacing and balloon angioplasty, applying new innovations to enhance these foundational device-based interventions and create more potent therapeutic solutions. At our inaugural R&D day in June, we were excited to share our insights into this renais
SC 13G/A - Medtronic plc (0001613103) (Subject)
SC 13G/A - Medtronic plc (0001613103) (Subject)
SC 13G/A - Medtronic plc (0001613103) (Subject)
Abbott Laboratories (NYSE:ABT) CEO Robert Ford said the company will use a mix of TV advertisements and guerilla marketing to promote the U.S. launch of Lingo, its glucose monitoring device. This device targets consumers without diabetes, aiming to personalize health data and enhance understanding of their health metrics. Also Read: Similac Baby Formula Maker Abbott And Reckitt Face Hundreds Of Baby Formula Lawsuits. Ford projected that Lingo could become a multi-billion-dollar product, although it is still in its nascent stage. Lingo, an over-the-counter device, is scheduled to launch this year alongside Libre Rio, which received FDA clearance last month. Abbott’s consumer bi
RBC Capital analyst Shagun Singh reiterates Medtronic (NYSE:MDT) with a Sector Perform and maintains $92 price target.
Medtronic (NYSE:MDT) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 5 0 2 Last 30D 0 0 1 0 0 1M Ago 0 0 1 0 0 2M Ago 0 1 3 0 2 3M Ago 0 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $88.25, a high estimate of $105.00, and a low estimate of $76.00. This current average represents a 1.79% decrease from the previ
SAN DIEGO, June 20, 2024 /PRNewswire/ -- Sempra (NYSE:SRE) (BMV:SRE) today announced the appointment of Jennifer M. Kirk to the company's board of directors effective June 20, 2024. Kirk is currently the global controller and chief accounting officer of Medtronic plc (NYSE:MDT) and has deep executive experience in finance, accounting and capital market activities, including more than 20 years in the energy industry. "Bringing new perspectives into the boardroom is a critical component of our effort to support the company's mission to build North America's premier energy infras
NORTHVILLE, Mich., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ:THRM), the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry and a leader in medical patient temperature management systems, today announced that Dr. Ken Washington has been appointed to the Company's Board of Directors, effective October 2, 2023. Dr. Washington is the Senior Vice President, Chief Technology and Innovation Officer of Medtronic plc (NYSE:MDT), a global healthcare technology company that provides device-based medical therapies and services. He was appointed to this position in June 2023, and he leads innovation and the expansion of technol
DUBLIN, June 26, 2023 /PRNewswire/ -- Medtronic announced today that its Board of Directors appointed Greg Lewis, Senior Vice President and Chief Financial Officer at Honeywell, to the Board. Lewis will serve on the Audit Committee and the Finance and Financial Risk Committee, effective June 26, 2023. "We are thrilled to have Greg Lewis join our Board. His background in financial leadership across multiple industries will be a strong asset as Medtronic pushes forward a comprehensive transformation that will set us up to deliver on durable growth," said Geoff Martha, Chairman and CEO of Medtronic. "I'm honored to join the Medtronic Board of Directors. I believe in the company's mission to al
Product innovation driving growth across diversified health tech portfolio, including Automated Insulin Delivery, Transcatheter Aortic Valve Replacement, Pulsed Field Cardiac Ablation, Pain Stimulation, and Deep Brain Stimulation GALWAY, Ireland, Aug. 20, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its first quarter (Q1) of fiscal year 2025 (FY25), which ended July 26, 2024. Key Highlights Revenue of $7.9 billion, adjusted revenue of $8.0 billion, increased 2.8% as reported and 5.3% organicGAAP diluted earnings per share (EPS) of $0.80; non-GAAP diluted EPS of $1.23Company increases FY25 organic revenue growth and EPS guidanceMultiple franchises deliv
GALWAY, Ireland, Aug. 16, 2024 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 15, 2024, approved the company's cash dividend for the second quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on October 11, 2024, to shareholders of record at the close of business on September 27, 2024. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, h
Broad-based, durable growth across the company, including Cranial & Spinal Technologies, Diabetes, Cardiac Pacing, Surgical, and Structural Heart; gaining momentum as company enters new product cycles across many high-growth markets DUBLIN, May 23, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its fourth quarter (Q4) and fiscal year 2024 (FY24), which ended April 26, 2024. Key Highlights Q4 revenue of $8.6 billion increased 0.5% as reported and 5.4% organicQ4 GAAP diluted earnings per share (EPS) of $0.49; non-GAAP diluted EPS of $1.46FY24 revenue of $32.4 billion increased 3.6% as reported and 5.2% organicFY24 GAAP diluted EPS of $2.76; non-GAAP dilute